ONTX News and Press, Onconova Therapeutics Inc. From 02/07/23

Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin lesions First evaluable participant has been in complete remission with no signs of metas...

NEWTOWN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating ...

NEWTOWN, Pa., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced their participation in the Channelchek Takeaway Series from the J.P...

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D....

NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the MedInvest Oncology Investor Confere...

NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth...

Onconova Therapeutics, Inc. (ONTX) Q3 2022 Results Conference Call November 14, 2022 04:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Dr. Steve Fruchtman - President & Chief Executive Officer Dr. Mark Gelder - Chief Medical...

Onconova Therapeutics press release ( NASDAQ: ONTX ): Q3 GAAP EPS of -$0.26 misses by $0.05 . Revenue of $0.06M (flat Y/Y) misses by $0.01M . Cash and cash equivalents as of September 30, 2022 were $42.6 million compared with $55.1 million as of December 31, 20...

Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”),...

Onconova Therapeutics ( NASDAQ: ONTX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $0.07M (+16.7% Y/Y). Over the last 1 year, ONTX has beaten EPS...